ACRS
Aclaris Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
0.00%
vs ±33.1% implied · ×0.00
shaded = implied · ▲▼ = realized
Fund move
Fund move
Aclaris Therapeutics, Inc.
3.98
−0.01 · −0.35%
post 3.98 0.00%
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | RA Capital ManagementRA Capital Management | $67.3M | 10.61% | +86.99% | |
| 2 | BML Capital ManagementBML | $63.3M | 9.99% | −15.96% | |
| 3 | BlackRockBlackRockindex-like | $53.1M | 8.37% | +35.51% | |
| 4 | Deep Track CapitalDeep Track Capital | $49.4M | 7.79% | 0.00% | |
| 5 | Vivo CapitalVivo Capital | $35.4M | 5.58% | +0.42% | |
| 6 | Vanguard Capital ManagementVanguardindex-like | $30.8M | 4.85% | +12.59% | |
| 7 | Frazier Life Sciences ManagementFrazier Life Sciences | $26.1M | 4.11% | 0.00% | |
| 8 | Rock Springs Capital ManagementRock Springs | $22.9M | 3.61% | −3.18% | |
| 9 | Adage Capital Partners GPAdage Capital Partners GP | $21.5M | 3.39% | +5.17% | |
| 10 | Decheng CapitalDecheng Capital | $21.4M | 3.37% | 0.00% | |
| 11 | State StreetState Streetindex-like | $17.2M | 2.71% | +62.06% | |
| 12 | Geode Capital ManagementGeodeindex-like | $16.9M | 2.66% | +31.62% | |
| 13 | Citadel AdvisorsCitadel | $12.6M | 1.99% | −15.29% | |
| 14 | BraidwellBraidwell | $11.3M | 1.79% | +26.09% | |
| 15 | Balyasny Asset ManagementBalyasny | $10.7M | 1.69% | −39.80% | |
| 16 | Silverarc Capital ManagementSilverarc | $10.3M | 1.62% | new | |
| 17 | Kalehua Capital ManagementKalehua | $9.7M | 1.53% | +36.99% | |
| 18 | Jones Hill CapitalJones Hill Capital | $9.3M | 1.47% | new | |
| 19 | Acadian Asset ManagementAcadian | $8.7M | 1.37% | +6.60% | |
| 20 | Palo Alto InvestorsPalo Alto Investors | $8.5M | 1.35% | 0.00% | |
| 21 | Woodline PartnersWoodline Partners | $8.5M | 1.34% | +8.44% | |
| 22 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $7.8M | 1.22% | −11.49% | |
| 23 | Panagora Asset ManagementPanagora | $7.2M | 1.13% | +169.99% | |
| 24 | Connor, Clark & Lunn Investment ManagementConnor, Clark & Lunn | $6.4M | 1.01% | −14.70% | |
| 25 | MPM Oncology Impact ManagementMPM Oncology Impact | $5.5M | 0.87% | +165.99% |
149 managers report $634.4M of Aclaris Therapeutics on form 13F for the quarter ended Jun 30 '26. 21 of them hold 80% of it; RA Capital Management is largest at 10.61%.
Linked news
NewsExpected move
Inputsspot 3.97exp Mar 19ATM strike 4ATM straddle 1.82IV 95%